Phylogica enters into Research and Licensing Agreement with Genentech
Advertisement
Phylogica Ltd announced that it has extended its collaboration with Genentech by entering into a Research and Licensing agreement to discover novel antibiotics. Phylogica will employ its Phylome® drug discovery platform, including its proprietary cellpenetrating peptide discovery technology to identify Phylomer peptides suitable for further evaluation.
Under the terms of the agreement, Phylogica will receive an upfront payment of US$500,000. In addition, Phylogica is eligible to receive research, development, and commercialization milestone payments totaling up to US$142 million.